Boston Scientific
No price chart data available for 1D timeframe.
Rating
Why Price Moved
Shares are down on concerns of a market slowdown d...
Key Statistics
Market Data
Valuation (TTM)
Valuation (NTM)
Cash Flow
Margins
Growth (CAGR)
Returns
Financial Health
Dividends
Profile
Boston Scientific Corporation (BSX) operates as a global leader in medical technology, specializing in the design, manufacturing, and commercialization of innovative medical devices tailored for a div...
Latest News
14 hours ago · zacks.com
Should You Book Profits or Hold BSX Stock Post-Q3 Earnings?Boston Scientific BSX saw modest sales growth in the third quarter, with revenues climbing 1.5% year over year to $5.14 billion, though its adjusted earnings per share (“EPS”) dipped 2.7% to 73 cents year over year. Primarily due to unexpected headwinds within two high-growth franchises, WATCHMAN and Electrophysiology (“EP”), the company lowered its expectations for the rest of the year.
3 days ago · zacks.com
Bear of the Day: Boston Scientific (BSX)I last wrote about Boston Scientific ( BSX ) as the Bear of the Day in early August after their Q2 report and management's lowered guidance propelled analysts to notch down their EPS estimates for this year and next, causing BSX shares to fall into the cellar of the Zacks Rank.
4 days ago · zacks.com
Boston Scientific Bets on WATCHMAN Growth Despite Market SlowdownBSX bets on WATCHMAN growth through clinical trials and physician outreach, even as slowing demand and rising competition cloud its outlook.
5 days ago · seekingalpha.com
Boston Scientific Corporation (BSX) Presents at Stifel 2026 Healthcare Conference 2026 TranscriptBoston Scientific Corporation (BSX) Presents at Stifel 2026 Healthcare Conference 2026 Transcript
5 days ago · marketbeat.com
Boston Scientific Targets Long-Term Growth as Key Businesses Face Pressure Through 2027Boston Scientific NYSE: BSX executives said they expect durable growth across the company's interventional portfolio, while acknowledging that its pulsed field ablation and WATCHMAN businesses face competitive challenges through 2027.
6 days ago · zacks.com
Wall Street Analysts Look Bullish on Boston Scientific (BSX): Should You Buy?Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employed (or sell-side) analysts often affect a stock's price, do they really matter?
12 days ago · zacks.com
Here is What to Know Beyond Why Boston Scientific Corporation (BSX) is a Trending StockBoston Scientific (BSX) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
13 days ago · zacks.com
BSX Q3 Results Reset Growth Expectations as 2027 Outlook Stays WeakBoston Scientific's cyber disruption cuts Q3 growth and earnings, forcing lower 2026 guidance as management sees 2027 as the cycle's trough.
14 days ago · zacks.com
Is BSX Worth Buying Now as Low Valuation Meets Weak Earnings Growth?Boston Scientific's steep valuation discount faces a major test as earnings estimates weaken, core franchises lose momentum and key growth catalysts shift to 2028.
14 days ago · prnewswire.com
SIMPLAAFY study of the WATCHMAN FLX™ Pro Left Atrial Appendage Closure Device meets primary endpointsBoth post-implant monotherapies in the trial achieved non-inferiority compared to dual anti-platelet therapy (DAPT) supporting the potential to simplify post-procedure drug regimens MARLBOROUGH, Mass. and SAN DIEGO, Nov. 2, 2026 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) today announced positive six-month primary endpoint results from the SIMPLAAFY randomized controlled trial of the WATCHMAN FLX™ Pro Left Atrial Appendage Closure (LAAC) Device.
Earnings
Analyst Summary
Add to Watchlist
Select watchlists to add or remove BSX